BriaCell Therapeutics Corp. (BCT.TO)
CAD 0.87
(-4.4%)
CAD 0.87
(-4.4%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -862.08 Thousand USD | 95.94% |
| 2023 | -21.25 Million USD | 48.22% |
| 2022 | -41.04 Million USD | 28.3% |
| 2021 | -57.24 Million USD | -27450.9% |
| 2020 | 209.29 Thousand CAD | 35.36% |
| 2019 | 154.61 Thousand CAD | -61.38% |
| 2018 | 400.39 Thousand CAD | 139.47% |
| 2017 | -1.01 Million CAD | -671.04% |
| 2016 | -131.57 Thousand CAD | 63.17% |
| 2015 | -357.23 Thousand CAD | 55.68% |
| 2014 | -806.08 Thousand CAD | 16.6% |
| 2013 | -966.52 Thousand CAD | 35.66% |
| 2012 | -1.5 Million CAD | 61.96% |
| 2011 | -3.94 Million CAD | -188.94% |
| 2010 | -1.36 Million CAD | -79.43% |
| 2009 | -761.68 Thousand CAD | -117.26% |
| 2008 | -350.57 Thousand CAD | 21.29% |
| 2007 | -445.42 Thousand CAD | -403.89% |
| 2006 | -88.39 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -6.24 Million USD | 54.24% |
| 2024 Q1 | -13.64 Million USD | 35.79% |
| 2024 Q3 | -935.69 Thousand USD | 85.02% |
| 2024 Q4 | -862.08 Thousand USD | 7.87% |
| 2023 Q4 | -21.25 Million USD | 24.56% |
| 2023 Q3 | -28.17 Million USD | 15.91% |
| 2023 Q2 | -33.5 Million USD | 10.55% |
| 2023 Q1 | -37.45 Million USD | 8.75% |
| 2023 FY | -21.25 Million USD | 48.22% |
| 2022 Q3 | -44.52 Million USD | 7.2% |
| 2022 Q2 | -47.98 Million USD | 13.49% |
| 2022 Q1 | -55.46 Million USD | 3.11% |
| 2022 FY | -41.04 Million USD | 28.3% |
| 2022 Q4 | -41.04 Million USD | 7.83% |
| 2021 Q2 | 380.83 Thousand CAD | 50.94% |
| 2021 FY | -57.24 Million USD | -27450.9% |
| 2021 Q1 | 252.3 Thousand CAD | 20.55% |
| 2021 Q4 | -57.24 Million USD | -185.11% |
| 2021 Q3 | -20.07 Million CAD | -5371.83% |
| 2020 Q2 | 79.72 Thousand CAD | 236.11% |
| 2020 Q4 | 209.29 Thousand CAD | 30.0% |
| 2020 FY | 209.29 Thousand CAD | 35.36% |
| 2020 Q1 | -58.57 Thousand CAD | -137.88% |
| 2020 Q3 | 160.99 Thousand CAD | 101.94% |
| 2019 Q3 | -386.29 Thousand CAD | -446.64% |
| 2019 Q1 | 523.4 Thousand CAD | 30.72% |
| 2019 FY | 154.61 Thousand CAD | -61.38% |
| 2019 Q4 | 154.61 Thousand CAD | 140.03% |
| 2019 Q2 | 111.44 Thousand CAD | -78.71% |
| 2018 Q3 | 712.29 Thousand CAD | 459.64% |
| 2018 FY | 400.39 Thousand CAD | 139.47% |
| 2018 Q4 | 400.39 Thousand CAD | -43.79% |
| 2018 Q2 | -198.05 Thousand CAD | 60.56% |
| 2018 Q1 | -502.16 Thousand CAD | 50.5% |
| 2017 Q1 | -97.98 Thousand CAD | 25.53% |
| 2017 Q4 | -1.01 Million CAD | -15.58% |
| 2017 FY | -1.01 Million CAD | -671.04% |
| 2017 Q3 | -877.74 Thousand CAD | -150.1% |
| 2017 Q2 | -350.96 Thousand CAD | -258.17% |
| 2016 Q4 | -131.57 Thousand CAD | 88.88% |
| 2016 Q1 | -53.03 Thousand CAD | 85.15% |
| 2016 Q3 | -1.18 Million CAD | -109.99% |
| 2016 Q2 | -563.67 Thousand CAD | -962.87% |
| 2016 FY | -131.57 Thousand CAD | 63.17% |
| 2015 Q2 | -314.03 Thousand CAD | 52.14% |
| 2015 FY | -357.23 Thousand CAD | 55.68% |
| 2015 Q3 | -253.93 Thousand CAD | 19.14% |
| 2015 Q4 | -357.23 Thousand CAD | -40.68% |
| 2015 Q1 | -656.09 Thousand CAD | 18.61% |
| 2014 FY | -806.08 Thousand CAD | 16.6% |
| 2014 Q4 | -806.08 Thousand CAD | 4.67% |
| 2014 Q3 | -845.59 Thousand CAD | 0.26% |
| 2014 Q2 | -847.83 Thousand CAD | 11.66% |
| 2014 Q1 | -959.68 Thousand CAD | 0.71% |
| 2013 Q3 | -1.06 Million CAD | 7.26% |
| 2013 Q2 | -1.15 Million CAD | 28.76% |
| 2013 Q1 | -1.61 Million CAD | -7.73% |
| 2013 FY | -966.52 Thousand CAD | 35.66% |
| 2013 Q4 | -966.52 Thousand CAD | 9.6% |
| 2012 Q4 | -1.5 Million CAD | 33.32% |
| 2012 Q3 | -2.25 Million CAD | 7.06% |
| 2012 Q2 | -2.42 Million CAD | 12.25% |
| 2012 Q1 | -2.76 Million CAD | 30.05% |
| 2012 FY | -1.5 Million CAD | 61.96% |
| 2011 Q1 | -1.28 Million CAD | 5.93% |
| 2011 Q2 | -1.1 Million CAD | 13.8% |
| 2011 Q3 | -6.99 Million CAD | -531.16% |
| 2011 Q4 | -3.94 Million CAD | 43.54% |
| 2011 FY | -3.94 Million CAD | -188.94% |
| 2010 Q1 | -615.94 Thousand CAD | 19.13% |
| 2010 Q3 | -1.54 Million CAD | -170.5% |
| 2010 Q2 | -572.44 Thousand CAD | 7.06% |
| 2010 FY | -1.36 Million CAD | -79.43% |
| 2010 Q4 | -1.36 Million CAD | 11.74% |
| 2009 Q3 | -352.29 Thousand CAD | -86.19% |
| 2009 Q4 | -761.68 Thousand CAD | -116.21% |
| 2009 Q2 | -189.21 Thousand CAD | 13.42% |
| 2009 Q1 | -218.54 Thousand CAD | 37.66% |
| 2009 FY | -761.68 Thousand CAD | -117.26% |
| 2008 FY | -350.57 Thousand CAD | 21.29% |
| 2008 Q4 | -350.57 Thousand CAD | 18.14% |
| 2008 Q3 | -428.28 Thousand CAD | 6.04% |
| 2008 Q2 | -455.83 Thousand CAD | 7.4% |
| 2008 Q1 | -492.26 Thousand CAD | -10.52% |
| 2007 Q4 | -445.42 Thousand CAD | 1.2% |
| 2007 Q2 | -434.4 Thousand CAD | 9.64% |
| 2007 Q3 | -450.85 Thousand CAD | -3.79% |
| 2007 Q1 | -480.75 Thousand CAD | 0.0% |
| 2007 FY | -445.42 Thousand CAD | -403.89% |
| 2006 FY | -88.39 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.09 Million CAD | 110.656% |
| Eupraxia Pharmaceuticals Inc. | -11.72 Million CAD | 92.646% |
| Helix BioPharma Corp. | -1.08 Million CAD | 20.251% |
| Microbix Biosystems Inc. | -4.96 Million CAD | 82.623% |
| Medicenna Therapeutics Corp. | -16.98 Million CAD | 94.924% |
| Satellos Bioscience Inc. | -22.06 Million CAD | 96.093% |
| Oncolytics Biotech Inc. | -31.11 Million CAD | 97.229% |
| Sernova Corp. | -8.58 Million CAD | 89.959% |